Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | TPO | P07202 | 1/20 | 0.33 |
| ▸ | EPX | P11678 | 1/20 | 0.33 |
| ▸ | LPO | P22079 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21630316 | 0.84 | CHRNB2 (0.36) | MPOTPOEPXLPOCHRNB2 | |
| SCHEMBL21630310 | 0.78 | MAPT (0.44) | LTA4HTSHR | |
| SCHEMBL901182 | 0.74 | MAOA (0.47) | LTA4HLMNACYP2C9SMN1; SMN2 | |
| SCHEMBL28564069 | 0.73 | GRM5 (0.36) | LMNA | |
| SCHEMBL8126363 | 0.73 | LMNA (0.61) | LTA4HLMNASMN1; SMN2 | |
| SCHEMBL21630308 | 0.71 | SOS1 (0.38) | — | |
| SCHEMBL21630390 | 0.71 | LTA4H (0.41) | LTA4HSMN1; SMN2 | |
| SCHEMBL21630305 | 0.71 | TEAD4 (0.44) | SMN1; SMN2 | |
| SCHEMBL28575004 | 0.71 | S1PR2 (0.34) | LTA4HLMNATSHRSMN1; SMN2 | |
| SCHEMBL28559740 | 0.71 | LOX (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031778-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031778-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | IPMK, PIP5K1B, PIP5K1C | MPO 1191/4885TPO 3149/4885EPX 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.